Talisman Therapeutics

Talisman Therapeutics is a private, preclinical-stage biotech founded in 2017 and based in Cambridge, UK. It operates a dual business model, focusing internally on discovering novel therapeutics for neurodegenerative diseases while also providing access to its human iPSC-based neuroscience platform to external partners. The company's core strategy is to overcome the limitations of traditional neurological drug discovery by using human genetics-informed, stem cell-derived models to identify and validate new targets and drug candidates.

A human neuroscience discovery platform combining human iPSC-derived neural cell types (e.g., neurons, microglia) with human genetics to engineer models of disease initiation and progression for drug discovery.

Talisman competes in the crowded neurodegenerative drug discovery space against large pharma (e.g., Biogen, Roche) and numerous biotechs. Its platform also competes with other iPSC/service providers (e.g., bit.bio, Axol Bioscience) and CROs offering neural disease models. Differentiation lies in its specific integration of human genetics and focus on microglial/lysosomal biology.